| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 258.357 +2.52% on 11/19/24 | | 336.000 -21.17% on 10/24/24 | -47.140 (-15.11%) since 10/18/24 |
| 3-Month | 242.000 +9.45% on 09/18/24 | | 336.000 -21.17% on 10/24/24 | -20.140 (-7.07%) since 08/19/24 |
| 52-Week | 190.400 +39.11% on 02/05/24 | | 353.000 -24.97% on 05/10/24 | -31.640 (-10.67%) since 11/17/23 |
SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited...
— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase...
— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for...
Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today...
HMPL-A83 is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and its second large molecule drug candidate to enter...
— 49% ORR amongst SAVANNAH patients with higher MET levels —...
SAN DIEGO and SHANGHAI and HONG KONG and SYDNEY, Australia, July 06, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 27, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13)...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13)...
| 3rd Resistance Point | 279.200 |
| 2nd Resistance Point | 275.600 |
| 1st Resistance Point | 270.300 |
| Last Price | 264.860 |
| 1st Support Level | 261.400 |
| 2nd Support Level | 257.800 |
| 3rd Support Level | 252.500 |
| 52-Week High | 353.000 |
| Fibonacci 61.8% | 290.887 |
| Fibonacci 50% | 271.700 |
| Last Price | 264.860 |
| Fibonacci 38.2% | 252.513 |
| 52-Week Low | 190.400 |